It is not clear whether other negative regulators are involved in the inactivation of ERK1/2 in adenomas harboring Kras mutations in this mouse model, but the absence of pERK1/2 in NNK‐induced adenomas suggests that regulatory mechanisms of ERK1/2 phosphorylation may function in lung precancerous lesions. The gene discussed is KRAS; the disease is adenoma.